Opportunities for nanotheranosis in lung cancer and pulmonary metastasis

Clinical and Translational Imaging

Volumn 2, Issue 5, 2014, Pages 427-437

  Key, J ^a   Kim, Y S ^a   Tatulli, F ^a   Palange, A L ^a   O'Neill B ^a   Aryal, S ^a   Ramirez, M ^a   Liu, X ^a   Ferrari, M ^a   Munden, R ^b   Decuzzi, P ^a,c  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

Multi modal imaging; Nanomedicine; Nanoparticles

Indexed keywords

NANOPARTICLE;

CANCER DIAGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER THERANOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; FLUORESCENCE IMAGING; HUMAN; LUNG CANCER; LUNG METASTASIS; NANOMEDICINE; NANOTHERANOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; REVIEW; THORAX RADIOGRAPHY;

EID: 84940638897     PISSN: 22815872     EISSN: 22817565     Source Type: Journal    
DOI: 10.1007/s40336-014-0078-7     Document Type: Review

References (35)

1. Cancer facts and figures (2014) American Cancer Society. http://www.cancer.org/research/cancerfactsstatistics/
2. Cancer (2013) Fact sheet No 297. World Health Organization. http://www.who.int/mediacentre/factsheets/fs297/en/
3. Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD, Tsuboi M, Vallières E, Goldstraw P, International Staging Committee, Cancer Research and Biostatistics, Observers to the Committee, Participating Institutions (2007) The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2:593–602
4. Murphy SL, Xu J, Kochanek KD (2013) National vital statistics report. Deaths: final data for 2010. Centers for Disease Control and Prevention 61(04). http://www.cdc.gov/nchs/products/nvsr.htm
5. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2013) SEER cancer statistics review, 1975–2010. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013
6. ® screening for pulmonary metastases. J Thorac Imaging 26:W1–W3
7. Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ, Wood DE, National Comprehensive Cancer Network (NCCN) (2006) Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 4(6):548–582
8. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395–409
9. Lynch TJ, Bogart JA, Curran WJ Jr, DeCamp MM, Gandara DR, Goss G, Henschke CI, Jett JR, Johnson BE, Kelly KL, Le Chevalier T, Mulshine JL, Scagliotti GV, Schiller JH, Shaw A, Thatcher N, Vokes EE, Wood DE, Hart C (2005) Early stage lung cancer—new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res 11(13 Pt 2):4981s–4983s
10. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500–2507
11. Vansteenkiste JF, Stroobants SG (2004) Positron emission tomography in the management of non-small cell lung cancer. Hematol Oncol Clin North Am 18:269–288
12. Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H, Bockisch A, Debatin JF, Freudenberg LS (2003) Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229:526–533
13. Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5:161–171
14. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760
15. Jain RK, Stylianopoulos T (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7:653–664
16. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–284
17. Decuzzi P, Pasqualini R, Arap W, Ferrari M (2009) Intravascular delivery of particulate systems: does geometry really matter? Pharm Res 26:235–243
18. Decuzzi P, Ferrari M (2008) Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials 29:377–384
19. Decuzzi P, Ferrari M (2006) The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials 27:5307–5314
20. Lee TR, Choi M, Kopacz AM, Yun SH, Liu WK, Decuzzi P (2013) On the near-wall accumulation of injectable particles in the microcirculation: smaller is not better. Sci Rep 3:2079
21. Aryal S, Hu CM, Zhang L (2010) Combinatorial drug conjugation enables nanoparticle dual-drug delivery. Small 6:1442–1448
22. Key J, Aryal S, Gentile F, Ananta JS, Zhong M, Landis MD, Decuzzi P (2013) Engineering discoidal polymeric nanoconstructs with enhanced magneto-optical properties for tumor imaging. Biomaterials 34:5402–5410
23. Shen J, Xu R, Mai J, Kim HC, Guo X, Qin G, Yang Y, Wolfram J, Mu C, Xia X, Gu J, Liu X, Mao ZW, Ferrari M, Shen H (2013) High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. ACS Nano 7:9867–9880
24. Ananta JS, Godin B, Sethi R, Moriggi L, Liu X, Serda RE, Krishnamurthy R, Muthupillai R, Bolskar RD, Helm L, Ferrari M, Wilson LJ, Decuzzi P (2010) Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol 5:815–821
25. Sethi R, Ananta JS, Karmonik C, Zhong M, Fung SH, Liu X, Li K, Ferrari M, Wilson LJ, Decuzzi P (2012) Enhanced MRI relaxivity of Gd(3 +) -based contrast agents geometrically confined within porous nanoconstructs. Contrast Media Mol Imaging 7:501–508
26. Aryal S, Key J, Stigliano C, Ananta JS, Zhong M, Decuzzi P (2013) Engineered magnetic hybrid nanoparticles with enhanced relaxivity for tumor imaging. Biomaterials 34:7725–7732
27. Gizzatov A, Key J, Aryal S, Ananta J, Cervadoro A, Palange AL, Fasano M, Stigliano C, Zhong M, Di Mascolo D, Guven A, Chiavazzo E, Asinari P, Liu X, Ferrari M, Wilson LJ, Decuzzi P (2014) Hierarchically structured magnetic nanoconstructs with enhanced relaxivity and cooperative tumor accumulation. Adv Funct Mater. doi:10.1002/adfm.201400653
28. Aryal S, Key J, Stigliano C, Landis MD, Lee DY, Decuzzi P (2014) Positron emitting magnetic nanoconstructs for PET/MR imaging. Small 10:2688–2696
29. Di Mascolo D, Lyon JC, Aryal S, Ramirez MR, Wang J, Candeloro P, Guindani M, Hsueh WA, Decuzzi P (2013) Rosiglitazone-loaded nanospheres for modulating macrophage-specific inflammation in obesity. J Control Release 170:460–468
30. Jones-Wilson TM, Deal KA, Anderson CJ, McCarthy DW, Kovacs Z, Motekaitis RJ, Sherry AD, Martell AE, Welch MJ (1998) The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nucl Med Biol 25:523–530
31. Godin B, Chiappini C, Srinivasan S, Alexander JF, Yokoi K, Ferrari M, Decuzzi P, Liu X (2012) Discoidal porous silicon particles: fabrication and biodistribution in breast cancer bearing mice. Adv Funct Mater 22:4225–4235
32. Blanco E, Sangai T, Hsiao A, Ferrati S, Bai L, Liu X, Meric-Bernstam F, Ferrari M (2013) Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. Cancer Lett 334:245–252
33. Shen H, Mittal V, Ferrari M, Chang J (2013) Delivery of gene silencing agents for breast cancer therapy. Breast Cancer Res 15:205
34. Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G (2013) Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res 19:1806–1815
35. Gizzatov A, Stigliano C, Ananta JS, Sethi R, Xu R, Guven A, Ramirez M, Shen H, Sood A, Ferrari M, Wilson LJ, Liu X, Decuzzi P (2014) Geometrical confinement of Gd(DOTA) molecules within mesoporous silicon nanoconstructs for MR imaging of cancer. Cancer Lett. doi:10.1016/j.canlet.2014.06.001